Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Autoimmune destruction of pericytes as the cause of diabetic retinopathy

Authors Duncan D Adams

Published 6 June 2008 Volume 2008:2(2) Pages 295—298

DOI http://dx.doi.org/10.2147/OPTH.S2629

Duncan D Adams

Faculty of Medicine, University of Otago, Dunedin, New Zealand

Abstract: In diabetic retinopathy, collapse of the retinal vasculature is associated with loss of the pericytes. These are contractile cells that together with endothelial cells form the terminal arterioles of the retina. The cause of the loss of pericytes is not known. Recently, it has been discovered that type 1 diabetes is caused by forbidden clones of cytotoxic T lymphocytes, which destroy the insulin-making cells with exquisite specificity. In the light of this, I postulate that an antigenically-related forbidden clone of cytotoxic T lymphocytes selectively destroys the pericytes and that this is the cause of the vascular collapse of diabetic retinopathy. If this is so, the therapeutic implications are immense, involving a switch from ineffectual tight glycemic control to immunotherapy. This is already used as immunosuppression to prevent organ transplant rejection, and as the immune ablation and autologous bone marrow cell reconstitution that has saved the lives of patients with lethally-severe scleroderma. Once the pericyte surface auto-antigen for the T lymphocytes has been isolated, selective destruction of the pathogenic T lymphocytes would be possible by manufacture and use of cytotoxic auto-antigen complexes, which arrests progression of the retinopathy.

Keywords: pericytes, diabetic retinopathy, autoimmunity, T cell forbidden clones, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Dual-color immunofluorescent labeling with quantum dots of the diabetes-associated proteins aldose reductase and Toll-like receptor 4 in the kidneys of diabetic rats

Liu XM, Hu R, Lian HW, Liu Y, Liu J, Liu JW, Lin GM, Liu LW, Duan XJ, Yong KT, Ye L

International Journal of Nanomedicine 2015, 10:3651-3662

Published Date: 20 May 2015

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R

Neuropsychiatric Disease and Treatment 2015, 11:51-57

Published Date: 30 December 2014

Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics

Takahashi PY, St Sauver JL, Finney Rutten LJ, Jacobson RM, Jacobson DJ, McGree ME, Ebbert JO

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:1-8

Published Date: 16 December 2014

Serum lipid profile and its association with hypertension in Bangladesh

Choudhury KN, Mainuddin AKM, Wahiduzzaman M, Islam SMS

Vascular Health and Risk Management 2014, 10:327-332

Published Date: 30 June 2014

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations

Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YTF

International Journal of Nanomedicine 2011, 6:2351-2366

Published Date: 14 October 2011

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf, et al

Vascular Health and Risk Management 2010, 6:525-539

Published Date: 29 June 2010

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart

Clinical Ophthalmology 2008, 2:613-621

Published Date: 12 September 2008

TNF-α-mediated inflammation in cerebral aneurysms: A potential link to growth and rupture

Thottala Jayaraman, Andrew Paget, Yang Sam Shin, Xiaguai Li, Jillian Mayer, et al

Vascular Health and Risk Management 2008, 4:805-817

Published Date: 8 August 2008

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension

Bruce I Gaynes, Anne Onyekwuluje

Clinical Ophthalmology 2008, 2:355-368

Published Date: 6 June 2008